Interferons and cognition

Journal of the Neurological Sciences

Volumn 245, Issue 1-2, 2006, Pages 137-140

  Montalban, X ^a   Rio, J ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Clinical trial; Cognitive function; Interferon beta; Multiple sclerosis

Indexed keywords

BETA INTERFERON;

ARTICLE; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; DISEASE CLASSIFICATION; DRUG EFFECT; HUMAN; MULTIPLE SCLEROSIS; PRIORITY JOURNAL;

CLINICAL TRIALS; COGNITION; HUMANS; INTERFERON-BETA; MULTIPLE SCLEROSIS;

EID: 33646851548     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2005.08.022     Document Type: Article

References (25)

1. Adams R.D., Victor M., and Ropper A.H. Principles of neurology. 8th ed. (1997), McGraw-Hill, New York
2. Arnold D.L., Riess G.T., Matthews P.M., Francis G.S., Collins D.L., Wolfson C., et al. Use of proton magnetic resonance spectroscopy for monitoring disease progression in multiple sclerosis. Ann Neurol 36 (1994) 76-82
3. Truyen L., van Waesberghe J.H., van Walderveen M.A., van Oosten B.W., Polman C.H., Hommes O.R., et al. Accumulation of hypointense lesions ("black holes") on T1 spin-echo MRI correlates with disease progression in multiple sclerosis. Neurology 47 (1996) 1469-1476
4. Trapp B.D., Peterson J., Ransohoff R.M., Rudick R., Mork S., and Bo L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 338 (1998) 278-285
5. Heaton R.K., Nelson L.M., Thompson D.S., Burks J.S., and Franklin G.M. Neuropsychological findings in relapsing-remitting and chronic-progressive multiple sclerosis. J Consult Clin Psychol 53 (1985) 103-110
6. Rao S.M., Leo G.J., Bernardin L., and Unverzagt F. Cognitive dysfunction in multiple sclerosis: I. Frequency, patterns, and prediction. Neurology 41 (1991) 685-691
7. Ryan L., Clark C.M., Klonoff H., and Paty D. Models of cognitive deficit and statistical hypotheses: multiple sclerosis, an example. J Clin Exp Neuropsychol 15 (1993) 563-577
8. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43 (1993) 655-661
9. Jacobs L.D., Cookfair D.L., Rudick R.A., Herndon R.M., Richert J.R., Salazar A.M., et al. Intramuscular interferon β-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 39 (1996) 285-294
10. PRIMS Study Group. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing-remitting multiple sclerosis. Lancet 352 (1998) 1498-1504
11. Paty D.W., Li D.K., for the University of British Columbia MS/MRI Study Group, and and the IFNβ Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43 (1993) 662-667
12. Simon J.H., et al., for the Multiple Sclerosis Collaborative Research Group. Magnetic Resonance studies of intramuscular interferon β-1a for the relapsing multiple sclerosis. Ann Neurol 43 (1998) 79-87
13. Li D.K., and Paty D.W. Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon β-1a in relapsing-remitting multiple sclerosis. Ann Neurol 46 (1999) 197-206
14. Dieperink E., Willenbring M., and Ho S.B. Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: a review. Am J Psychiatry 157 (2000) 867-876
15. Fisher J.S. Assessment of neuropsychological function in multiple sclerosis. In: Cohen J.A., and Rudick R.A. (Eds). Multiple sclerosis therapeutics (2003), Martin Dunitz 37-59
16. Pliskin N.H., Hamer D.P., Goldstein D.S., Towle V.L., Reder A.T., Noronha A., et al. Improved delayed visual reproduction test performance in multiple sclerosis patients receiving interferon beta-1b. Neurology 47 (1996 (Dec.)) 1463-1468
17. Barak Y., and Achiron A. Effect of interferon-beta-1b on cognitive functions in multiple sclerosis. Eur Neurol 47 (2002) 11-14
18. Selby M.J., Ling N., Williams J.M., and Dawson A. Interferon beta 1-b in verbal memory functioning of patients with relapsing-remitting multiple sclerosis. Percept Mot Skills 86 (1998) 1099-1106
19. Fischer J.S., Priore R.L., Jacobs L.D., Cookfair D.L., Rudick R.A., Herndon R.M., et al. Neuropsychological effects of interferon beta-1a in relapsing multiple sclerosis. Ann Neurol 48 (2000) 885-892
20. European Study Group on interferon β-1b in secondary progressive MS. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS. Lancet 352 9139 (1998) 1491-1497
21. Cohen J.A., Cutter G.R., Fischer J.S., Goodman A.D., Heidenreich F.R., Kooijmans M.F., et al. Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. Neurology 59 (2002) 679-687
22. Revesz T., Kidd D., Thompson A.J., Barnard R.O., and McDonald W.I. A comparison of the pathology of primary and secondary multiple sclerosis. Brain 117 (1994) 759-765
23. Montalban X., Brieva L., Tintore M., Borras C., Rio J., Nos, et al. Single centre, DBPC, randomised trial of interferon beta-1b in primary progressive and transitional progressive multiple sclerosis: an exploratory phase II study. Mult Scler 8 Suppl. 1 (2002) S134
24. Borras C., Porcel J., Brieva L., Tintoré M., Rio J., Arévalo M.J., et al. Neuropsychological performance in patients with primary and transitional progressive multiple sclerosis treated with interferon beta-1b. Mult Scler 9 Suppl 1 (2003) S144
25. Benedict R.H., Fischer J.S., Archibald C.J., Arnett P.A., Beatty W.W., Bobholz J., et al. Minimal neuropsychological assessment of MS patients: a consensus approach. Clin Neuropsychol 16 (2002) 381-397